Ding! Ding! Ding! The Weihe Molecular Classroom is now giving a lecture

Weihe Molecular Classroom 2- Long term Infusion of Hematological Diseases and the First Step of Matching Platelets

Background analysis:

Blood diseases often make people shudder, but we are not powerless. The main treatment methods for blood diseases include hormone, immunoglobulin or other hormones, immunosuppressive agents, etc. However, in the early stage of low platelet count, the main harm is bleeding, ranging from skin and mucosal bleeding to visceral bleeding, and in severe cases, it can be life-threatening. Patients with acute myeloid leukemia, transplant related diseases, aplastic anemia, myelodysplastic syndrome (MDS), idiopathic thrombocytopenic purpura (ITP), neonatal thrombocytopenia, acute lymphocytic leukemia, solid tumors, chronic myelopathy, and non Hodgkin's disease all require platelet transfusion to prolong their lives. Therefore, the first step in the treatment of blood diseases is to maintain a safe and stable level of platelets, while allowing subsequent treatments to be effective (producing healthy platelets themselves) without bleeding and away from the risk of complications. Platelet matching infusion is the only way to stabilize platelet count.

Autologous stem cell transplantation (ASCT) is the main method for treating malignant hematological diseases, especially in the treatment of acute non lymphocytic leukemia, malignant lymphoma and other diseases. When the hematopoietic and immune functions of the patient's bone marrow are almost exhausted, the transfusion of autologous stem cells can help the patient rebuild hematopoiesis and restore immunity while completely removing residual tumor cells. Therefore, ASCT remains the diagnostic and treatment method for most patients with hematological diseases.

CAR-T immunotherapy is also a rapidly developing new type of cellular immunotherapy technology in recent years. Its basic principle is to genetically modify the patient's own immune cells, namely T lymphocytes, and then modify, process, and cultivate T cells that can meet the treatment requirements. Then, they are reintroduced into the body and cleared of cancer cells. Therefore, the modified T lymphocytes can specifically recognize tumor cells to express antigen targets, thereby activating T lymphocytes and effectively killing leukemia and tumor cells. At present, for malignant hematological diseases that are difficult to treat and have failed conventional treatment, leukemia, lymphoma, and multiple myeloma are powerful killers with excellent therapeutic effects

However, whether it is ASCT or CAR-T therapy, how to stabilize platelet count at a safe value and reduce complications such as bleeding and infection has always been a new area of exploration for experts. Xiao Yang, Director of the Hematology Department of Jinshazhou Cancer Hospital, Guangzhou University of Chinese Medicine, has also explored how to stabilize platelet count and reduce bleeding points during the treatment of hematological diseases in clinical practice. He shared two real cases of hematological patients with a call on all clinical doctors to do platelet HPA and HLA typing in advance, and make appointments for matching platelet transfusions during transplantation, in order to greatly reduce the number of platelet transfusions and accelerate hematopoietic reconstruction; In addition, in CAR-T therapy, Director Xiao's experience is that the infusion of matched platelets can help safely pass through the bone marrow suppression period and reduce platelet transfusion dependence.

Title: Case Sharing of ASCT and CAR-T Treatment for MM (Platelet Matching Infusion Case Sharing)

Speaker: Professor Xiao Yang

Introduction by Professor Xiao Yang

·Director of Hematology and Oncology Department, Jinshazhou Hospital, Guangzhou University of Traditional Chinese Medicine
·Distinguished Professor at the Translational Medicine Center of the Second Affiliated Hospital of Guangzhou Medical University
·Vice Chairman of the Hematology Professional Committee of the Military Science and Technology Committee
·Vice President and Chairman of the Hematology Branch of the Asia Pacific Medical Bioimmunology Society
·China Medical Quality Management Association Stem Cell and Precision Medicine
·Vice President of Quality Management Branch
·Director of the Cell Therapy Research and Application Branch of the Chinese Society of Cell Biology
·Vice Chairman of the 7th and 8th Hematology Branch of Guangdong Medical Association
·Member of the 9th Hematology Branch of the Chinese Medical Association
·Vice Chairman of the Cell Biotherapy Professional Committee of Guangdong Anti Cancer Association
·Vice Chairman of Hematology Branch of Guangdong Health Association
·Standing Committee Member of the Cell Therapy Branch of Guangdong Medical Association
·Expert in the evaluation of the National Natural Science Foundation of China

[Contact Information]

Address: 225300, East Side, 2nd Floor, Building G75, Phase 4, Yaocheng, Medical High tech Zone, Taizhou City, Jiangsu Province

Phone: 0523-86201335-8010 (product consultation)

Website: www.wehelpinc.com

Email: sales@wehelpinc.com

Previous article： Ding! Ding! Ding! The Weihe Molecular Classroom is now giving a lecture

Next article： The list of national drug standard substance collaborative calibration laboratories has been released